MedTrace Logo

VedAryo® (Vedolizumab) Effectiveness and Safety Evaluation

NCT07273760 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2025-12-10

No results posted yet for this study

Summary

The aim of this observational study is to evaluate Effectiveness and safety of VedAryo® (Vedolizumab) in male or female participants with clinical diagnosis of Inflammatory Bowel Disease. The main questions are aim to answer:

1. Is VedAryo® (Vedolizumab) effective in the treatment of Inflammatory Bowel Disease?
2. Is VedAryo® (Vedolizumab) safe in the treatment of Inflammatory Bowel Disease?

In this study, there is no comparison group. Participants received VedAryo® (Vedolizumab)

Conditions

  • Ulcerative Colitis (UC)
  • Crohn Disease (CD)
  • Inflammatory Bowel Disease (IBD)

Interventions

DRUG

Vedolizumab

Vedolizumab administered IV with a suggested dose of 300 mg at 0, 2, and 6 weeks and then once every 8 weeks

Sponsors & Collaborators

  • AryoGen Pharmed Co.

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-16
Primary Completion
2025-09-30
Completion
2025-10-05

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07273760 on ClinicalTrials.gov